nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—AOX1—Methotrexate—lymphatic system cancer	0.378	0.607	CbGbCtD
Raloxifene—CYP3A4—Cytarabine—lymphatic system cancer	0.0778	0.125	CbGbCtD
Raloxifene—CYP3A4—Teniposide—lymphatic system cancer	0.0766	0.123	CbGbCtD
Raloxifene—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0536	0.0859	CbGbCtD
Raloxifene—CYP3A4—Vincristine—lymphatic system cancer	0.0369	0.0591	CbGbCtD
Raloxifene—Retinal vein thrombosis—Methotrexate—lymphatic system cancer	0.016	0.0438	CcSEcCtD
Raloxifene—Deep vein thrombosis—Fludarabine—lymphatic system cancer	0.00932	0.0255	CcSEcCtD
Raloxifene—Cholelithiasis—Fludarabine—lymphatic system cancer	0.00912	0.0249	CcSEcCtD
Raloxifene—Coronary artery disease—Vincristine—lymphatic system cancer	0.00877	0.024	CcSEcCtD
Raloxifene—Thromboembolic event—Methotrexate—lymphatic system cancer	0.00624	0.0171	CcSEcCtD
Raloxifene—EBP—Azacitidine—Fludarabine—lymphatic system cancer	0.00573	0.514	CbGdCrCtD
Raloxifene—EBP—Azacitidine—Cytarabine—lymphatic system cancer	0.00541	0.486	CbGdCrCtD
Raloxifene—Depression—Mechlorethamine—lymphatic system cancer	0.00488	0.0134	CcSEcCtD
Raloxifene—Tenderness—Bleomycin—lymphatic system cancer	0.00477	0.013	CcSEcCtD
Raloxifene—Cerebrovascular accident—Fludarabine—lymphatic system cancer	0.0042	0.0115	CcSEcCtD
Raloxifene—Cystitis noninfective—Bleomycin—lymphatic system cancer	0.00406	0.0111	CcSEcCtD
Raloxifene—Cystitis—Bleomycin—lymphatic system cancer	0.00402	0.011	CcSEcCtD
Raloxifene—Bladder pain—Bleomycin—lymphatic system cancer	0.00376	0.0103	CcSEcCtD
Raloxifene—Pulmonary embolism—Carmustine—lymphatic system cancer	0.00363	0.00993	CcSEcCtD
Raloxifene—Sweating—Teniposide—lymphatic system cancer	0.00346	0.00947	CcSEcCtD
Raloxifene—Vertigo—Mechlorethamine—lymphatic system cancer	0.00344	0.0094	CcSEcCtD
Raloxifene—Bronchitis—Fludarabine—lymphatic system cancer	0.00342	0.00936	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00324	0.00885	CcSEcCtD
Raloxifene—Pneumonia—Fludarabine—lymphatic system cancer	0.00319	0.00873	CcSEcCtD
Raloxifene—Arthritis—Bleomycin—lymphatic system cancer	0.00311	0.0085	CcSEcCtD
Raloxifene—Infection—Mechlorethamine—lymphatic system cancer	0.0031	0.00849	CcSEcCtD
Raloxifene—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00308	0.00844	CcSEcCtD
Raloxifene—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.00308	0.00843	CcSEcCtD
Raloxifene—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00306	0.00836	CcSEcCtD
Raloxifene—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00303	0.0083	CcSEcCtD
Raloxifene—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00303	0.00829	CcSEcCtD
Raloxifene—Flushing—Teniposide—lymphatic system cancer	0.00301	0.00823	CcSEcCtD
Raloxifene—Sinusitis—Fludarabine—lymphatic system cancer	0.00298	0.00814	CcSEcCtD
Raloxifene—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00283	0.00775	CcSEcCtD
Raloxifene—Pharyngitis—Fludarabine—lymphatic system cancer	0.00283	0.00773	CcSEcCtD
Raloxifene—Deep vein thrombosis—Methotrexate—lymphatic system cancer	0.00276	0.00756	CcSEcCtD
Raloxifene—Vaginal discharge—Methotrexate—lymphatic system cancer	0.00276	0.00756	CcSEcCtD
Raloxifene—Embolism—Methotrexate—lymphatic system cancer	0.00262	0.00716	CcSEcCtD
Raloxifene—Chest pain—Teniposide—lymphatic system cancer	0.0024	0.00657	CcSEcCtD
Raloxifene—Pneumonia—Bleomycin—lymphatic system cancer	0.00234	0.0064	CcSEcCtD
Raloxifene—Infection—Teniposide—lymphatic system cancer	0.00229	0.00626	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00226	0.0062	CcSEcCtD
Raloxifene—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00225	0.00617	CcSEcCtD
Raloxifene—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00223	0.00609	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00221	0.00603	CcSEcCtD
Raloxifene—Cough—Fludarabine—lymphatic system cancer	0.00216	0.00592	CcSEcCtD
Raloxifene—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00214	0.00584	CcSEcCtD
Raloxifene—Myalgia—Fludarabine—lymphatic system cancer	0.00211	0.00577	CcSEcCtD
Raloxifene—Arthralgia—Fludarabine—lymphatic system cancer	0.00211	0.00577	CcSEcCtD
Raloxifene—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00208	0.00568	CcSEcCtD
Raloxifene—Pneumonia—Carmustine—lymphatic system cancer	0.00204	0.00559	CcSEcCtD
Raloxifene—Depression—Carmustine—lymphatic system cancer	0.00202	0.00554	CcSEcCtD
Raloxifene—Infection—Fludarabine—lymphatic system cancer	0.00201	0.0055	CcSEcCtD
Raloxifene—Vomiting—Mechlorethamine—lymphatic system cancer	0.00199	0.00543	CcSEcCtD
Raloxifene—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00198	0.00543	CcSEcCtD
Raloxifene—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00198	0.00542	CcSEcCtD
Raloxifene—Urinary tract infection—Carmustine—lymphatic system cancer	0.00197	0.0054	CcSEcCtD
Raloxifene—Rash—Mechlorethamine—lymphatic system cancer	0.00197	0.00539	CcSEcCtD
Raloxifene—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00197	0.00538	CcSEcCtD
Raloxifene—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00196	0.00535	CcSEcCtD
Raloxifene—Pneumonia—Vincristine—lymphatic system cancer	0.00195	0.00533	CcSEcCtD
Raloxifene—Flushing—Bleomycin—lymphatic system cancer	0.00194	0.0053	CcSEcCtD
Raloxifene—Depression—Vincristine—lymphatic system cancer	0.00193	0.00529	CcSEcCtD
Raloxifene—Weight increased—Mitoxantrone—lymphatic system cancer	0.00193	0.00527	CcSEcCtD
Raloxifene—Pneumonia—Mitoxantrone—lymphatic system cancer	0.0019	0.00519	CcSEcCtD
Raloxifene—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00188	0.00515	CcSEcCtD
Raloxifene—Sweating—Vincristine—lymphatic system cancer	0.00186	0.00508	CcSEcCtD
Raloxifene—Nausea—Mechlorethamine—lymphatic system cancer	0.00185	0.00507	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00184	0.00504	CcSEcCtD
Raloxifene—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00183	0.00502	CcSEcCtD
Raloxifene—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00183	0.00502	CcSEcCtD
Raloxifene—Abdominal pain—Teniposide—lymphatic system cancer	0.00182	0.00498	CcSEcCtD
Raloxifene—Body temperature increased—Teniposide—lymphatic system cancer	0.00182	0.00498	CcSEcCtD
Raloxifene—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00181	0.00496	CcSEcCtD
Raloxifene—Sweating—Mitoxantrone—lymphatic system cancer	0.00181	0.00495	CcSEcCtD
Raloxifene—Oedema peripheral—Carmustine—lymphatic system cancer	0.0018	0.00491	CcSEcCtD
Raloxifene—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00179	0.0049	CcSEcCtD
Raloxifene—Dyspepsia—Fludarabine—lymphatic system cancer	0.00178	0.00487	CcSEcCtD
Raloxifene—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00177	0.00484	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00175	0.00478	CcSEcCtD
Raloxifene—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00173	0.00474	CcSEcCtD
Raloxifene—Pain—Fludarabine—lymphatic system cancer	0.00173	0.00473	CcSEcCtD
Raloxifene—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00172	0.0047	CcSEcCtD
Raloxifene—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00171	0.00468	CcSEcCtD
Raloxifene—Urethral disorder—Vincristine—lymphatic system cancer	0.00171	0.00467	CcSEcCtD
Raloxifene—Rhinitis—Mitoxantrone—lymphatic system cancer	0.0017	0.00465	CcSEcCtD
Raloxifene—Flushing—Carmustine—lymphatic system cancer	0.00169	0.00463	CcSEcCtD
Raloxifene—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00168	0.0046	CcSEcCtD
Raloxifene—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00168	0.0046	CcSEcCtD
Raloxifene—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00168	0.0046	CcSEcCtD
Raloxifene—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00164	0.00449	CcSEcCtD
Raloxifene—Cystitis—Methotrexate—lymphatic system cancer	0.00162	0.00444	CcSEcCtD
Raloxifene—Cardiac disorder—Vincristine—lymphatic system cancer	0.00161	0.00442	CcSEcCtD
Raloxifene—Body temperature increased—Fludarabine—lymphatic system cancer	0.0016	0.00438	CcSEcCtD
Raloxifene—Vaginal infection—Methotrexate—lymphatic system cancer	0.00159	0.00434	CcSEcCtD
Raloxifene—Cough—Bleomycin—lymphatic system cancer	0.00159	0.00434	CcSEcCtD
Raloxifene—Angiopathy—Vincristine—lymphatic system cancer	0.00158	0.00432	CcSEcCtD
Raloxifene—Diarrhoea—Teniposide—lymphatic system cancer	0.00158	0.00431	CcSEcCtD
Raloxifene—Myalgia—Bleomycin—lymphatic system cancer	0.00155	0.00423	CcSEcCtD
Raloxifene—Chest pain—Bleomycin—lymphatic system cancer	0.00155	0.00423	CcSEcCtD
Raloxifene—Bladder pain—Methotrexate—lymphatic system cancer	0.00152	0.00416	CcSEcCtD
Raloxifene—Infection—Bleomycin—lymphatic system cancer	0.00147	0.00403	CcSEcCtD
Raloxifene—Vomiting—Teniposide—lymphatic system cancer	0.00146	0.004	CcSEcCtD
Raloxifene—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00145	0.00397	CcSEcCtD
Raloxifene—Rash—Teniposide—lymphatic system cancer	0.00145	0.00397	CcSEcCtD
Raloxifene—Dermatitis—Teniposide—lymphatic system cancer	0.00145	0.00397	CcSEcCtD
Raloxifene—Headache—Teniposide—lymphatic system cancer	0.00144	0.00395	CcSEcCtD
Raloxifene—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.0014	0.00384	CcSEcCtD
Raloxifene—Diarrhoea—Fludarabine—lymphatic system cancer	0.00138	0.00379	CcSEcCtD
Raloxifene—Nausea—Teniposide—lymphatic system cancer	0.00137	0.00374	CcSEcCtD
Raloxifene—Vertigo—Vincristine—lymphatic system cancer	0.00136	0.00372	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00135	0.0037	CcSEcCtD
Raloxifene—Chest pain—Carmustine—lymphatic system cancer	0.00135	0.0037	CcSEcCtD
Raloxifene—Myalgia—Carmustine—lymphatic system cancer	0.00135	0.0037	CcSEcCtD
Raloxifene—Myalgia—Vincristine—lymphatic system cancer	0.00129	0.00353	CcSEcCtD
Raloxifene—Cough—Mitoxantrone—lymphatic system cancer	0.00129	0.00352	CcSEcCtD
Raloxifene—Infection—Carmustine—lymphatic system cancer	0.00129	0.00352	CcSEcCtD
Raloxifene—Vomiting—Fludarabine—lymphatic system cancer	0.00129	0.00352	CcSEcCtD
Raloxifene—Rash—Fludarabine—lymphatic system cancer	0.00128	0.00349	CcSEcCtD
Raloxifene—Dermatitis—Fludarabine—lymphatic system cancer	0.00127	0.00349	CcSEcCtD
Raloxifene—Pain—Bleomycin—lymphatic system cancer	0.00127	0.00347	CcSEcCtD
Raloxifene—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00127	0.00347	CcSEcCtD
Raloxifene—Headache—Fludarabine—lymphatic system cancer	0.00127	0.00347	CcSEcCtD
Raloxifene—Chest pain—Mitoxantrone—lymphatic system cancer	0.00126	0.00344	CcSEcCtD
Raloxifene—Myalgia—Mitoxantrone—lymphatic system cancer	0.00126	0.00344	CcSEcCtD
Raloxifene—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00126	0.00344	CcSEcCtD
Raloxifene—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00125	0.00341	CcSEcCtD
Raloxifene—Infection—Vincristine—lymphatic system cancer	0.00123	0.00336	CcSEcCtD
Raloxifene—Nervous system disorder—Vincristine—lymphatic system cancer	0.00121	0.00332	CcSEcCtD
Raloxifene—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00121	0.00331	CcSEcCtD
Raloxifene—Nausea—Fludarabine—lymphatic system cancer	0.0012	0.00329	CcSEcCtD
Raloxifene—Infection—Mitoxantrone—lymphatic system cancer	0.0012	0.00327	CcSEcCtD
Raloxifene—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0012	0.00327	CcSEcCtD
Raloxifene—Shock—Mitoxantrone—lymphatic system cancer	0.00118	0.00324	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00118	0.00323	CcSEcCtD
Raloxifene—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00118	0.00322	CcSEcCtD
Raloxifene—Body temperature increased—Bleomycin—lymphatic system cancer	0.00117	0.00321	CcSEcCtD
Raloxifene—Insomnia—Carmustine—lymphatic system cancer	0.00117	0.0032	CcSEcCtD
Raloxifene—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00117	0.0032	CcSEcCtD
Raloxifene—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00116	0.00318	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00113	0.00308	CcSEcCtD
Raloxifene—Insomnia—Vincristine—lymphatic system cancer	0.00112	0.00306	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00112	0.00306	CcSEcCtD
Raloxifene—Pain—Carmustine—lymphatic system cancer	0.00111	0.00303	CcSEcCtD
Raloxifene—Breast disorder—Methotrexate—lymphatic system cancer	0.0011	0.00302	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.0011	0.003	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00107	0.00292	CcSEcCtD
Raloxifene—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00106	0.0029	CcSEcCtD
Raloxifene—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00106	0.0029	CcSEcCtD
Raloxifene—Pain—Vincristine—lymphatic system cancer	0.00106	0.00289	CcSEcCtD
Raloxifene—Pain—Mitoxantrone—lymphatic system cancer	0.00103	0.00282	CcSEcCtD
Raloxifene—Abdominal pain—Carmustine—lymphatic system cancer	0.00102	0.0028	CcSEcCtD
Raloxifene—Body temperature increased—Carmustine—lymphatic system cancer	0.00102	0.0028	CcSEcCtD
Raloxifene—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00101	0.00277	CcSEcCtD
Raloxifene—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000984	0.00269	CcSEcCtD
Raloxifene—Body temperature increased—Vincristine—lymphatic system cancer	0.000977	0.00267	CcSEcCtD
Raloxifene—Abdominal pain—Vincristine—lymphatic system cancer	0.000977	0.00267	CcSEcCtD
Raloxifene—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000952	0.0026	CcSEcCtD
Raloxifene—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000952	0.0026	CcSEcCtD
Raloxifene—Pneumonia—Methotrexate—lymphatic system cancer	0.000946	0.00259	CcSEcCtD
Raloxifene—Vomiting—Bleomycin—lymphatic system cancer	0.000943	0.00258	CcSEcCtD
Raloxifene—Depression—Methotrexate—lymphatic system cancer	0.000938	0.00257	CcSEcCtD
Raloxifene—Rash—Bleomycin—lymphatic system cancer	0.000935	0.00256	CcSEcCtD
Raloxifene—Dermatitis—Bleomycin—lymphatic system cancer	0.000934	0.00256	CcSEcCtD
Raloxifene—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000914	0.0025	CcSEcCtD
Raloxifene—Sweating—Methotrexate—lymphatic system cancer	0.000902	0.00247	CcSEcCtD
Raloxifene—Diarrhoea—Carmustine—lymphatic system cancer	0.000886	0.00242	CcSEcCtD
Raloxifene—Nausea—Bleomycin—lymphatic system cancer	0.000881	0.00241	CcSEcCtD
Raloxifene—Dizziness—Carmustine—lymphatic system cancer	0.000856	0.00234	CcSEcCtD
Raloxifene—Diarrhoea—Vincristine—lymphatic system cancer	0.000846	0.00231	CcSEcCtD
Raloxifene—Pharyngitis—Methotrexate—lymphatic system cancer	0.000838	0.00229	CcSEcCtD
Raloxifene—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000834	0.00228	CcSEcCtD
Raloxifene—Urethral disorder—Methotrexate—lymphatic system cancer	0.000828	0.00226	CcSEcCtD
Raloxifene—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000824	0.00225	CcSEcCtD
Raloxifene—Vomiting—Carmustine—lymphatic system cancer	0.000823	0.00225	CcSEcCtD
Raloxifene—Dizziness—Vincristine—lymphatic system cancer	0.000817	0.00224	CcSEcCtD
Raloxifene—Rash—Carmustine—lymphatic system cancer	0.000816	0.00223	CcSEcCtD
Raloxifene—Dermatitis—Carmustine—lymphatic system cancer	0.000816	0.00223	CcSEcCtD
Raloxifene—Headache—Carmustine—lymphatic system cancer	0.000811	0.00222	CcSEcCtD
Raloxifene—Vomiting—Vincristine—lymphatic system cancer	0.000786	0.00215	CcSEcCtD
Raloxifene—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000784	0.00214	CcSEcCtD
Raloxifene—Rash—Vincristine—lymphatic system cancer	0.000779	0.00213	CcSEcCtD
Raloxifene—Dermatitis—Vincristine—lymphatic system cancer	0.000779	0.00213	CcSEcCtD
Raloxifene—Headache—Vincristine—lymphatic system cancer	0.000774	0.00212	CcSEcCtD
Raloxifene—Nausea—Carmustine—lymphatic system cancer	0.000769	0.0021	CcSEcCtD
Raloxifene—Angiopathy—Methotrexate—lymphatic system cancer	0.000766	0.0021	CcSEcCtD
Raloxifene—Vomiting—Mitoxantrone—lymphatic system cancer	0.000765	0.00209	CcSEcCtD
Raloxifene—Rash—Mitoxantrone—lymphatic system cancer	0.000759	0.00208	CcSEcCtD
Raloxifene—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000758	0.00207	CcSEcCtD
Raloxifene—Headache—Mitoxantrone—lymphatic system cancer	0.000754	0.00206	CcSEcCtD
Raloxifene—Nausea—Vincristine—lymphatic system cancer	0.000734	0.00201	CcSEcCtD
Raloxifene—Nausea—Mitoxantrone—lymphatic system cancer	0.000715	0.00196	CcSEcCtD
Raloxifene—Vertigo—Methotrexate—lymphatic system cancer	0.00066	0.00181	CcSEcCtD
Raloxifene—Cough—Methotrexate—lymphatic system cancer	0.000641	0.00175	CcSEcCtD
Raloxifene—Arthralgia—Methotrexate—lymphatic system cancer	0.000626	0.00171	CcSEcCtD
Raloxifene—Chest pain—Methotrexate—lymphatic system cancer	0.000626	0.00171	CcSEcCtD
Raloxifene—Myalgia—Methotrexate—lymphatic system cancer	0.000626	0.00171	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000621	0.0017	CcSEcCtD
Raloxifene—Infection—Methotrexate—lymphatic system cancer	0.000596	0.00163	CcSEcCtD
Raloxifene—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000588	0.00161	CcSEcCtD
Raloxifene—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000587	0.00161	CcSEcCtD
Raloxifene—Skin disorder—Methotrexate—lymphatic system cancer	0.000583	0.00159	CcSEcCtD
Raloxifene—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00058	0.00159	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000546	0.00149	CcSEcCtD
Raloxifene—Insomnia—Methotrexate—lymphatic system cancer	0.000542	0.00148	CcSEcCtD
Raloxifene—Dyspepsia—Methotrexate—lymphatic system cancer	0.000528	0.00144	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000518	0.00142	CcSEcCtD
Raloxifene—Pain—Methotrexate—lymphatic system cancer	0.000513	0.0014	CcSEcCtD
Raloxifene—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00049	0.00134	CcSEcCtD
Raloxifene—Abdominal pain—Methotrexate—lymphatic system cancer	0.000474	0.0013	CcSEcCtD
Raloxifene—Body temperature increased—Methotrexate—lymphatic system cancer	0.000474	0.0013	CcSEcCtD
Raloxifene—Diarrhoea—Methotrexate—lymphatic system cancer	0.00041	0.00112	CcSEcCtD
Raloxifene—Dizziness—Methotrexate—lymphatic system cancer	0.000397	0.00109	CcSEcCtD
Raloxifene—Vomiting—Methotrexate—lymphatic system cancer	0.000381	0.00104	CcSEcCtD
Raloxifene—Rash—Methotrexate—lymphatic system cancer	0.000378	0.00103	CcSEcCtD
Raloxifene—Dermatitis—Methotrexate—lymphatic system cancer	0.000378	0.00103	CcSEcCtD
Raloxifene—Headache—Methotrexate—lymphatic system cancer	0.000376	0.00103	CcSEcCtD
Raloxifene—Nausea—Methotrexate—lymphatic system cancer	0.000356	0.000975	CcSEcCtD
